Tsai A L, Vijjeswarapu H, Wu K K
Department of Internal Medicine, University of Texas Health Science Center, Houston 77225.
Biochim Biophys Acta. 1988 Jul 21;942(2):220-6. doi: 10.1016/0005-2736(88)90023-5.
Iloprost, a stable analog of prostacyclin, has been used for studying the interaction between prostacyclin and its effector cells such as platelets and vascular cells. The compound is usually prepared as a mixture of 16(S) and 16(R) stereoisomers. In this work, we compared the biological activity and platelet receptor binding characteristics between the two isomers. The 16(S) isomer was 20-times more potent than the 16(R) in inhibiting collagen-induced platelet aggregation. Equilibrium binding of iloprost isomers to platelet membrane receptors measured by rapid filtration method revealed that the specific binding data of 16(S) isomer was fit for a single binding species with Kd of 13.4 nM and Bmax 665 fmol/mg protein. By contrast, the Kd and Bmax of 16(R) isomer were 288 nM and 425 fmol/mg, respectively. To further assess different binding behavior of these two isomers, association rate was measured. The observed association rate of the S isomer was 0.036 s-1 and 0.001 s-1 for the R isomer at 15 nM iloprost and 2 mg/ml platelet membrane proteins. We postulate that the striking difference in the association rate with resultant difference in binding affinity and biologic activity between the two isomers was due to fitting of the molecule to the receptor channel. The 16(S) form has a more favorable orientation for fitting into the receptor. We conclude that the two iloprost isomers must be considered as two entirely different compounds when iloprost is used as the ligand for quantifying prostacyclin receptor binding.
依洛前列素是前列环素的一种稳定类似物,已被用于研究前列环素与其效应细胞(如血小板和血管细胞)之间的相互作用。该化合物通常制备成16(S)和16(R)立体异构体的混合物。在这项研究中,我们比较了两种异构体之间的生物活性和血小板受体结合特性。16(S)异构体在抑制胶原蛋白诱导的血小板聚集方面比16(R)异构体强20倍。通过快速过滤法测量依洛前列素异构体与血小板膜受体的平衡结合,结果显示16(S)异构体的特异性结合数据符合单一结合类型,解离常数(Kd)为13.4 nM,最大结合量(Bmax)为665 fmol/mg蛋白质。相比之下,16(R)异构体的Kd和Bmax分别为288 nM和425 fmol/mg。为了进一步评估这两种异构体不同的结合行为,我们测量了结合速率。在15 nM依洛前列素和2 mg/ml血小板膜蛋白的条件下,观察到S异构体的结合速率为0.036 s-1,R异构体为0.001 s-1。我们推测,两种异构体在结合速率上的显著差异以及由此导致的结合亲和力和生物活性的差异是由于分子与受体通道的契合度不同。16(S)形式在契合受体方面具有更有利的取向。我们得出结论,当依洛前列素用作定量前列环素受体结合的配体时,必须将两种依洛前列素异构体视为两种完全不同的化合物。